Owkin provides an AI-driven platform that integrates multimodal patient data from a federated network of hospitals to generate and test drug discovery hypotheses at scale. Its autonomous AI Scientist, K Pro, identifies biomarkers, matches therapies to patient subpopulations, and optimizes clinical trial design, continuously learning from real‑world outcomes to accelerate biopharma development.
Funding
$139M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+5Founders
Product
Problem
Drugdiscovery and development are slowed by the complexity of patient biology and the difficulty of integrating large, multimodal patient datasets (genomics, imaging, clinical records). Traditional approaches struggle to identify the right patient subpopulations and predictive biomarkers, leading to inefficient clinical trials and delayed delivery of targeted therapies.
Solution
Owkin has created an autonomous AI Scientist called K Pro that acts as a single decision‑making agent for biopharma. The platform ingests multimodal patient data from a federated network of over 100 hospitals and applies large‑language‑model‑based biology, specialized AI skills, and intelligent orchestration to generate and test hypotheses at scale. By linking AI predictions with wet‑lab validation, K Pro discovers novel biomarkers, matches drugs to patient subpopulations, and optimizes trial design (population definition, enrichment, external control arms). The system continuously learns from real‑world outcomes, ensuring that insights remain up‑to‑date and clinically relevant.
Target Audience
Primary customers are pharmaceutical and biotech companies, contract research organizations, and academic research institutions that need AI‑enhanced insights for drug discovery, clinical‑trial optimization, and diagnostic development.
Features
- AI Scientist (K Pro)
- an agentic platform that dynamically selects and combines specialized AI skills for drug discovery, development, and diagnostics.
- Access to the world’s largest multimodal patient data network (104+ hospitals) via a privacy‑preserving federated learning hub.
- MOSAIC spatial & multi‑omics dataset (2,700 cancer samples across 11 tumor types) for biomarker and target discovery.
- Intelligent orchestration framework that integrates user‑provided data, custom agents, and ensures ISO27001/GDPR compliance and interpretability.
- Autonomous hypothesis generation with a lab‑in‑the‑loop feedback cycle that validates AI predictions experimentally.
- Tools for patient‑population definition, clinical‑trial enrichment, and AI‑generated external control arms.
- Dedicated AI modules for target discovery (TargetMATCH) and drug positioning (DrugMATCH).